Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine

doi:10.3748/wjg.v24.i48.5462

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 48

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9027)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-10) series, Tables (1-1) series.

Item

Count

PDF

531

WORD

293

HTML

4934

Figures (1-10)

298

Tables (1-1)

534

Sum=6590

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

911

Download

1526

Sum=2437

Dec 28, 2018 (publication date) through Jan 12, 2025

Times Cited of This Article

Times Cited (35)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Dec 28, 2018; 24(48): 5462-5476
Published online Dec 28, 2018. doi: 10.3748/wjg.v24.i48.5462

Table 1 Assessed cecum lesion (sum of longest diameters, mm, at mucosal site (M) and serosal site (S), means ± SD) and adhesion severity (score 0-7, Min/Med/Max)

Medication (/kg, 10 ml/2 min bath/rat)	Assessed cecum lesion (sum of longest diameters, mm, means ± SD) and adhesion severity (score 0-9, Min/Med/Max)
	Day 1		Day 7
	Perforated cecum lesion	Adhesion severity	Perforated cecum lesion	Adhesion severity
0.9%NaCl (control)	5.0 ± 0.5 (M)	3/3/3	5.0 ± 0.5 (M)	3/4/4
0.9%NaCl (control)	5.0 ± 0.5 (S)	3/3/3	6.0 ± 0.5 (S)	3/4/4
BPC 157 (10 µg)	3.0 ± 0.0 (M)^a	1/1/1^a	0.0 ± 0.0 (M)^a	1/1/2^a
BPC 157 (10 µg)	3.0 ± 0.0 (S)^a	1/1/1^a	0.0 ± 0.0 (S)^a	1/1/2^a
L-NAME 5 mg	7.5 ± 0.4 (M)^a	5/6/6^a	8.0 ± 0.4 (M)^a	6/6/6^a
L-NAME 5 mg	7.5 ± 0.5 (S)^a	5/6/6^a	8.8 ± 0.5 (S)^a	6/6/6^a
L-arginine 100 mg	7.0 ± 0.0 (M)^a	4/5/5^a	7.5 ± 0.3 (M)^a	5/6/6^a
L-arginine 100 mg	7.0 ± 0.0 (S)	4/5/5^a	8.0 ± 0.4 (S)^a	5/6/6^a
L-NAME 5 mg +	7.3 ± 0.5 (M)	5/6/6^a	8.0 ± 0.3 (M)	5/6/6^a
L-arginine 100 mg	7.3 ± 0.5 (S)	5/6/6^a	8.2 ± 0.5 (S)	5/6/6^a
L-NAME 5 mg + BPC 157 10 μg	3.0 ± 0.0 (M)^a	1/1/1^a	0.0 ± 0.0 (M)^a	1/1/2^a
L-NAME 5 mg + BPC 157 10 μg	3.0 ± 0.0 (S)^a	1/1/1^a	0.0 ± 0.0 (S)^a	1/1/2^a
L-arginine 100 mg + BPC 157 10 μg	3.0 ± 0.0 (M)^a	1/1/1^a	0.0 ± 0.0 (M)^a	1/1/2^a
L-arginine 100 mg + BPC 157 10 μg	3.0 ± 0.0 (S)^a	1/1/1^a	0.0 ± 0.0 (S)^a	1/1/2^a
L-NAME 5 mg + L-arginine 100 mg + BPC 157 10 μg	3.0 ± 0.0 (M)^a	0/1/1^a	0.0 ± 0.0 (M)^a	1/1/2^a
L-NAME 5 mg + L-arginine 100 mg + BPC 157 10 μg	3.0 ± 0.0 (S)^a	0/1/1^a	0.0 ± 0.0 (S)^a	1/1/2^a

At 1 min post-injury, administration of medication (/kg, 10 mL/2 min bath/rat) at the perforated (5 mm diameter) lesion and cecum, includes BPC 157 (10 µg), NOS-blocker L-NAME (5 mg), NOS-substrate L-arginine (100 mg) alone or combined, a saline bath of equal volume (controls), and rats were left after abdominal closure undisturbed till the sacrifice, at day 1 or day 7. Minimum

^aP < 0.05 vs control.

Citation: Drmic D, Samara M, Vidovic T, Malekinusic D, Antunovic M, Vrdoljak B, Ruzman J, Milkovic Perisa M, Horvat Pavlov K, Jeyakumar J, Seiwerth S, Sikiric P. Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine. World J Gastroenterol 2018; 24(48): 5462-5476
URL: https://www.wjgnet.com/1007-9327/full/v24/i48/5462.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i48.5462